Skip navigation

Novo Nordisk hit by near $1 billion transfer pricing tax claim: TV

COPENHAGEN (Reuters) - Novo Nordisk <NOVOb.CO>, the world's biggest insulin producer, is facing a tax claim for 5.5 billion Danish crowns ($975 million) from the Danish authorities in a dispute over transfer pricing, local television broadcaster DR said on Monday. Full story

Novo Nordisk says obesity drug trial confirms weight loss

COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, said Phase III study results had shown people treated with its liraglutide drug had an 8 percent weight loss. Full story

Novo Nordisk says completes hemophilia drug trial

COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, said on Friday it had completed the first phase III trial of a hemophilia drug, N9-GP. Full story

Novo Nordisk obesity drug results underwhelm investors

COPENHAGEN (Reuters) - Overweight and obese diabetes patients given high doses of Novo Nordisk's drug liraglutide achieved 6 percent weight loss in a clinical trial, only slightly above the loss seen in those on a lower dose. Full story

Novo Nordisk gets green light for Tresiba in Europe

COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, said on Monday it got the final go-ahead from authorities to market its long-acting diabetes drug Tresiba in Europe. Full story

Jump in Diabetes Seen Among Youth

   Drugmakers are tapping into the growing diabetes market, with CNBC's Seema Mody, and Dr. Alan Moses, Novo Nordisk chief medical officer.

Sponsored Links
advertisement | ad info

Related Photos

Handout shows the new long-acting insulin Tresiba drug on a Novo Nordisk production line
Handout shows the new long-acting insulin Tresiba drug on a Novo Nordisk production line

The new long-acting insulin Tresiba drug is seen on a Novo Nordisk production line, in this 2012 handout picture provided by Novo Nordisk. U.S. regulators on February 10, 2013 dealt a major blow to Novo Nordisk's hopes for its new long-acting insulin Tresiba by demanding the Danish drugmaker conduct

Handout shows an employee working on a Novo Nordisk production line for the new long-acting insulin Tresiba drug
Handout shows an employee working on a Novo Nordisk production line for the new long-acting insulin Tresiba drug

An employee works on a Novo Nordisk production line for the new long-acting insulin Tresiba drug, in this August 18, 2012 handout picture provided by Novo Nordisk. U.S. regulators on February 10, 2013 dealt a major blow to Novo Nordisk's hopes for its new long-acting insulin Tresiba by demanding the

Sorensen President and CEO of Novo Nordisk
Sorensen President and CEO of Novo Nordisk

Lars Rebien Sorensen President and Chief Executive Officer of Novo Nordisk is seen September 26, 2010, in this picture provided by Novo Nordisk. Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish